Seeking Alpha
  • colebunn
    Opinions on why investors don't seem to care about $BLUE acquiring Pregenen? Seems exciting/promising for $BLUE believers
    7/2/14
    Reply (2)
    • Blackbeard: Hard to move needle when products are still many years from actual sale. Continued proof of concept/safety studies will affect stock more.
      7/2/14
    • colebunn: Absolutely, but this technology should improve the delivery efficiency of their products - which is often an issue in gene therapy
      7/3/14
      From other sites